5002572025-10-012025-12-315002572025-04-012025-12-315002572025-10-012025-12-31in-capmkt:OtherExpenses1Member5002572025-10-012025-12-31in-capmkt:OtherExpenses2Member5002572025-04-012025-12-31in-capmkt:OtherExpenses1Member5002572025-04-012025-12-31in-capmkt:OtherExpenses2Member5002572025-10-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572025-04-012025-12-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15002572025-10-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss15002572025-04-012025-12-31ItemsThatWillBeReclassifiedToProfitAndLoss1iso4217:INRiso4217:INRxbrli:shares500257LUPINNOTLISTEDINE326A01037Lupin LimitedMain BoardEquity2025-04-012026-03-312026-02-122026-01-28INRMillionsQuarterlyThird quarterSingle segmentPharmaceuticals2026-02-1218:30:002026-02-1220:40:00Not applicablefalsefalseThe disclosure for the default on Loans and Debt Securities is not applicable to the Company.2025-10-012025-12-31UnauditedStandalone450119000009980000004600990000090955000002961300000-17520000063151000003602000001786800000106484000003099210000015017800000-6338400000867940000014140000009090000015049000000717450000000007174500000-588000007115700000913700000215.7115.670015.7115.671. The above Standalone Financial Results were reviewed by the Audit Committee and thereafter approved and taken on record by the Board of Directors at their meeting held on February 12, 2026. The Statutory Auditors of the Company have carried out limited review of the above Standalone Financial Results pursuant to Regulation 33 of the SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. <BR> <BR> 2. During the quarter ended December 31, 2025, 40,938 year to date 233,761 equity shares of Rs. 2- each, fully paid-up, were allotted upon exercise of the vested stock options pursuant to the Lupin Employees Stock Option Plans ESOPs, resulting in an increase in the paid-up equity share capital by Rs. 0.1 million year to date Rs. 0.5 million and securities premium account by Rs. 40.9 million year to date Rs. 256.5 million. <BR> <BR> 3. Exceptional items <BR> <BR> a. Lupin Limited and its US subsidiary were named in class action and individual cases related to Antitrust Litigations for certain products. The Company intends to settle the matter with certain parties without admitting any liability for any wrongdoing and accordingly has created a provision of Rs. 4,493.9 million USD 50.0 million during the quarter and nine months ended December 31, 2025. <BR> <BR> b. On February 09, 2026, Lupin Limited and its subsidiary entered into a settlement agreement with Astellas towards ongoing dispute related to Mirabegron ER Tablets a generic version of Myrbetriq ER Tablets in US markets. The Company has agreed to pay USD 90.0 million, which includes USD 75.0 million towards Prepaid Option. During the quarter and nine months ended December 31, 2025 the Company has provided Rs. 1,348.1 million USD 15.0 million for one time payment towards this settlement. <BR> <BR> c. The Government of India has consolidated 29 existing labour legislations into a unified framework comprising four labour codes as follows: Code on Wages, 2019, Code on Social Security, 2020, Industrial Relations Code, 2020 and Occupational Safety, Health and Working Conditions Code, 2020 collectively referred to as the New Labour Codes. The New Labour Codes are effective from November 21, 2025 and introduce changes that include, among other things, setting a uniform definition of wages. The Company has assessed the implications of the New Labour Codes and has recognized an incremental cost of Rs. 496.4 million during the quarter and nine months ended December 31, 2025. The Company continues to monitor the developments pertaining to the New Labour Codes and the impact, if any, will be accounted in accordance with applicable accounting standards. <BR> <BR> d. During the quarter ended September 30, 2025 and nine months ended December 31, 2025, the Company transferred its Over the Counter OTC and API RandD business in India to its wholly owned subsidiaries Lupinlife Consumer Healthcare Limited and Lupin Manufacturing Solutions Limited respectively, as a going concern on slump sale basis for a consideration of Rs. 8,200.0 million and Rs. 180.0 million resulting in gain on divestment of Rs. 6,589.6 million and Rs. 37.2 million respectively, subject to working capital adjustments. <BR> <BR> e. During the quarter ended September 30, 2025 and nine months ended December 31, 2025, the Company has determined that the carrying value of investment in a subsidiary is higher than the recoverable amount and has provided for diminution in the value of investment of Rs. 700.0 million. During the quarter, nine months ended December 31, 2024 and year ended March 31, 2025, the Company had provided for diminution in the value of investments in subsidiaries of Rs. 772.2 million. <BR> <BR> 4. During the nine months ended December 31, 2024 and year ended March 31, 2025, Lupin Limited and its subsidiary, agreed to settle the dispute for an amount of Rs. 750.5 million USD 9.0 million in connection with the drug Glumetza® without admitting any liability for any wrongdoing, with a view to avoid the costs and uncertainties of continued litigation. <BR> <BR> 5. During the year ended March 31, 2025, the Company has recognised an impairment charge of Rs. 410.9 million related to property, plant and equipment, commercialised intangibles and capital work in progress. <BR> 2025-04-012025-12-31UnauditedStandalone1427806000002239400000145020000000268283000009177400000381700000188423000008270000005301300000323314000009368940000051330600000-411600000509190000008801700000886000008890300000042028700000000042028700000-23590000041792800000913700000292.0291.780092.0291.78Other Expenses (refer note 4)11321800000Net (gain) / loss on foreign currency transactions-673400000Other Expenses (refer note 4)35492300000Net (gain) / loss on foreign currency transactions-3160900000(i) Items that will not be reclassified subsequently to profit or loss-77400000-77400000(i) Items that will not be reclassified subsequently to profit or loss1540000015400000-270000005400000(i) Items that will be reclassified subsequently to profit or loss-12900000-12900000(i) Items that will be reclassified subsequently to profit or loss-378000000-378000000-4500000-132100000-58800000-235900000